Year archive

Quantumzyme Corp. — 2026 filings

All 10 regulatory filings released by Quantumzyme Corp. (QTZM) in 2026, sourced directly from the official regulator.

10 Filings

2026 Period

2026 filings (10)

Filing	Released	Lang
Quantum Genesis AI Announces Removal of OTC Markets Caveat Emptor Designation Regulatory Filings	2026-06-01	English
Quantum Genesis AI Issues Clarification Regarding Research Activities and Intellectual Property Regulatory Filings	2026-05-19	English
Quantum Genesis AI Corp. Issues Statement Regarding OTC Markets Caveat Emptor Designation Regulatory Filings	2026-03-12	English
Quantumzyme Research Published in the Journal of Molecular Graphics & Modelling Study Highlights In Silico Enzyme Engineering Approach for Sustainable Drug Manufacturing Regulatory Filings	2026-02-12	English
Quantumzyme Announces Strategic Capital Structure Initiative, Corporate Rebranding Update, and Planned 4-for-1 Forward Stock Split Share Issue/Capital Change	2026-02-09	English
Quantumzyme Featured on Cover of RSC Sustainability for Research in Enzyme Engineering for Ibuprofen Synthesis Regulatory Filings	2026-01-30	English
Quantumzyme to Attend 2026 BIO International Convention Regulatory Filings	2026-01-28	English
Quantumzyme Announces Next-Generation Enzyme Engineering Platform for More Efficient Pharmaceutical Manufacturing Regulatory Filings	2026-01-27	English
Quantumzyme Corp. Provides 2025 Corporate Update and Outlines Strategic Priorities for 2026 Regulatory Filings	2026-01-26	English
Quantumzyme Corp. Announces Memorandum of Understanding With Predictive Research Inc. to Explore AI-Enabled Applications in Green Chemistry and Biocatalysis Regulatory Filings	2026-01-16	English